Lindex

Quick links to important sections

Lindex

Method of action: Psychoanaleptics

Treatment option: Dementia, Vascular Dementia

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lindex

Property Description
Active ingredient Memantine Hydrochloride
Form Tablets (Film-Coated), Oral Solution
Pharmacological class Central Nervous System (CNS) Agent, NMDA Receptor Antagonist
General purpose Support and stabilize cognitive function in adult patients
Origin Synthetic compound (Amantadine derivative)

Lindex is a prescribed pharmaceutical drug classified as a Central Nervous System (CNS) Agent, primarily recognized within the therapeutic category of Anti-dementia Agents. The active ingredient, Memantine Hydrochloride, is a synthetic amantadine derivative with a recognized mechanism of action. The regulatory classification confirms its use to manage conditions characterized by cognitive decline, specifically targeting stabilization of functional abilities in adult patients.

Composition and Available Forms of Lindex

The composition of Lindex is based solely on the active compound Memantine Hydrochloride, making it a monotherapy. This medicine is manufactured for oral administration and is most commonly supplied as film-coated tablets. However, Lindex may also be available as an aqueous oral solution. This variation in dosage form is a distinguishing feature, often beneficial for geriatric patients who may experience difficulty swallowing solid medications.

General Purpose and Action of Lindex

The general purpose of Lindex is clinically recognized to help support core cognitive functions, such as memory and thinking ability, by modulating specific, excessive chemical activity in the brain.

The action of Memantine is rooted in its role as an uncompetitive NMDA receptor antagonist. By regulating the activity of the glutamatergic system, Lindex helps to reduce the chronic, unwanted nerve cell signaling, known as excitotoxicity, within the brain. This regulating function is intended to help preserve the remaining integrity of neuronal communication and sustain a patient's functional capacity.

Regulatory References

  1. Ebixa (Memantine) EPAR

What side effects are possible with Lindex?

Possible Side Effects and Safety Information

The safety profile of Lindex (Memantine Hydrochloride) is classified by regulatory agencies based on clinical trial data and subsequent postmarketing experience. The official labeling outlines common adverse reactions, rare but serious events, and specific safety considerations.


Documented Adverse Reactions

Adverse reactions are formally categorized by the body system affected and frequency.

Classification Common Side Effects (Trial Incidence 5% and > Placebo) Affected System-Organ Classes
Trial Data Dizziness, Headache, Confusion, Constipation, Diarrhea Nervous System, Gastrointestinal, Psychiatric

Postmarketing surveillance has documented serious adverse reactions that are considered rare or of unknown frequency. These include events affecting multiple systems, such as Acute Renal Failure, Hepatitis, Congestive Cardiac Failure, Pancreatitis, and specific blood disorders (e.g., Agranulocytosis). Suicidal ideation and severe skin reactions like Stevens Johnson syndrome have also been reported.


Safety Constraints and Considerations

The regulatory profile identifies specific limitations and patient-related cautions:

  • Contraindication: Lindex is formally contraindicated in patients with a known hypersensitivity to the active substance, Memantine, or any of the product's excipients.
  • Renal and Hepatic Impairment: Caution is necessary in patients with severe renal impairment or severe hepatic impairment, as the drug's elimination may be reduced.
  • Urine pH Influence: Conditions that significantly raise the urine pH (such as certain diets or medications) may reduce the body's clearance of Memantine, potentially leading to increased blood levels and a possible increase in adverse effects.
  • Seizures: While not systematically evaluated in all patients with seizure history, seizures have been reported in clinical trials.

Overdose and Emergency Response

Overdose and when to seek help

Lindex (Memantine Hydrochloride) overdose may present with a range of officially documented signs, primarily affecting the Central Nervous System (CNS). These manifestations include confusion, somnolence, vertigo, agitation, hallucination, and gait disturbance. Gastrointestinal symptoms such as vomiting and diarrhoea may also occur. In cases of acute, very large overdose, the regulatory documents report the potential for severe systemic outcomes. These can include psychotic reactions, a proconvulsive state (risk of seizure), and significant CNS depression leading to coma or unconsciousness. Cardiovascular effects such as tachycardia (rapid heart rate) and hypertension have also been noted in these severe exposure scenarios.


The official regulatory guidance strictly mandates that individuals must seek immediate medical attention or get medical advice if a large overdose is accidentally taken. Prompt contact with a Poison Control Center or the nearest hospital emergency department is required. Management of Lindex overdose is symptomatic and supportive, as no specific antidote is available.

Regulator-defined procedures that may be utilized include gastric lavage and the administration of Carbo medicinalis (activated charcoal). Additionally, the official labeling notes that conditions which raise urine pH (e.g., severe infections) may lead to reduced drug clearance, increasing the risk of accumulation and toxicity.

Therapeutic Uses of Lindex

What Lindex Treats: Main Uses and Benefits

Lindex (Memantine Hydrochloride) is commonly used to help with the symptomatic management of conditions associated with dementia, such as Alzheimer's disease. This application is relevant when supportive symptom management is appropriate for older adults.

The core therapeutic domains include symptoms related to cognitive impairment, functional stability, and associated behavioral disturbances. In general clinical scenarios, Lindex is commonly used to help with core symptoms related to cognitive decline, including difficulties with memory, focused attention, and general confusion. This supportive relief may assist with maintaining a sense of stability in cognitive function, which helps patients cope more steadily with symptom fluctuations.

“Lindex is generally applied in contexts where additional symptomatic support is needed, contributing to easing the overall symptom load.”

It is considered relevant for easing the impact of symptoms that affect functional stability and is applied in situations where patients experience challenging behavioral symptoms, including pronounced agitation or aggression.


Quick Fact: Symptomatic Support
Lindex is relevant for managing symptom clusters that may become intense or disruptive, such as behavioral and psychological disturbances (BPSD) in adult patients with chronic neurodegenerative conditions.

Regulatory References

  1. FDA Drug Label for Memantine Hydrochloride

Eligibility and Restrictions for Use

Lindex (Memantine Hydrochloride) is governed by specific eligibility rules established by regulatory authorities. These rules define the populations permitted, restricted, or prohibited from using the medicine.

Contraindications and Prohibited Use

Lindex is contraindicated in patients with a known hypersensitivity (allergy) to memantine hydrochloride or to any other ingredients in the formulation.

Age and Developmental Status

Use is approved only for adult patients (aged 18 years and over). The medicine is not recommended for use in children and adolescents below 18 years, as safety and efficacy data have not been established in this age group.

Organ Function and Physiological Restrictions

The use of Lindex is subject to restrictions based on certain organ functions:

Restriction Regulatory Status
Severe Hepatic Impairment (Child-Pugh C) Not recommended due to a lack of available data.
Severe Renal Impairment (CrCl 5–29 mL/min) Requires a reduction of the standard maintenance dose.

Conditions that cause urine pH to increase (e.g., severe urinary tract infections) require caution as they may reduce the body's elimination of the drug. For pregnancy and lactation, use is not recommended.

What should I know about interactions with other medicines?

Documented Interactions with Lindex

Interactions with NMDA Antagonists

Co-administration with other N-methyl-D-aspartate (NMDA) receptor antagonists is a documented interaction restriction. Official regulatory information advises avoiding combinations with substances such as amantadine, ketamine, and dextromethorphan due to the potential for pronounced additive central nervous system (CNS) related adverse reactions.

Pharmacokinetic Interactions: Renal Clearance

The profile of Lindex is highly influenced by its renal elimination pathway, which involves the cationic transport system. Substances that utilize the same transport mechanism may compete for clearance, potentially leading to increased plasma levels of Lindex. These include cimetidine, ranitidine, quinidine, and nicotine.

Exposure Modifiers and Urinary pH

Lindex clearance is sensitive to urinary pH. The co-administration of urinary alkalinizing agents, such as sodium bicarbonate and carbonic anhydrase inhibitors (e.g., acetazolamide), can decrease Lindex's elimination rate, which may result in increased systemic exposure. Pathological conditions that cause alkaline urine, such as renal tubular acidosis and severe urinary tract infections, present the same risk and require caution.

Pharmacodynamic Effects and Monitoring

The effects of L-dopa, dopaminergic agonists, and anticholinergics may be enhanced. Conversely, the effects of neuroleptics and barbiturates may be reduced. When co-administered with warfarin or other oral anticoagulants, close monitoring of the International Normalised Ratio (INR) is officially advised.

Mechanism of Action

How Lindex Works

The mechanism of action for Lindex is centered on the selective regulation of the brain's main excitatory pathways, leading to the modulation of neural signaling patterns.


Modulation of Pathological Glutamatergic Signaling

Lindex's active compound, Memantine, primarily acts as an uncompetitive antagonist of the N-methyl-D-aspartate (NMDA) receptor, a key ion channel for the neurotransmitter glutamate. This mechanism is highly targeted: the drug functions as an open-channel blocker that preferentially engages the receptor when it is excessively and pathologically overactive; the rapid off-rate kinetics permit transient physiological signaling.


Mitigating the Excitotoxicity Cascade

Excessive NMDA receptor activation results in the prolonged influx of calcium ions ( Ca^2+), which initiates the cellular cascade known as excitotoxicity. By physically blocking the receptor channel, Memantine limits this harmful Ca^2+ overload, thereby suppressing this destructive biochemical cascade. The physiological result is the mitigation of excitotoxicity which influences the integrity of neuronal communication pathways.

Dosage and Administration Information

How Lindex is Used: Official Administration Guidelines

Lindex (Memantine Hydrochloride) is administered orally and is available as immediate-release film-coated tablets and an oral solution. Its use follows a highly structured regimen, emphasizing a gradual dose increase over the initial weeks of therapy.


Official Dosing and Administration Schedule

Treatment begins with a low starting dose of 5 mg once daily. The dosage is then increased in increments of 5 mg at a minimum interval of one week between increases to allow the body to adjust to the compound. This titration leads to the standardized maintenance dose of 20 mg per day, which is typically administered as 10 mg twice daily. The maximum recommended daily dose is 20 mg.

Administration Scope Procedural Rule
With or Without Food Tablets may be taken with or without food.
Oral Solution Handling Must be measured using the supplied dosing device and should not be mixed with any other liquid.
Missed Dose Protocol If a single dose is missed, patients should not double up the next dose; the next dose should be taken as scheduled.
Renal Impairment For patients with severe renal impairment, the maximum daily dose is adjusted downward to 10 mg per day.

Contextual Use

Lindex is prescribed as part of a long-term plan for symptomatic management, and the decision to initiate and supervise treatment must be made by a physician. If treatment is interrupted for several days, it may be necessary to restart the regimen at a lower dose and follow the standard weekly titration schedule to safely resume therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research into the Combination Treatment

Research explored the study of the combination therapy in models of moderate to severe conditions.

  • Trial Design Focus: Studies evaluated the combination of the two active ingredients as part of the trial design.
  • Treatment Goals: Research examined the drug’s potential to affect the frequency of severe flare-ups, observing outcomes related to symptom reduction over a 12-month period.

Comparison to Monotherapies

Research has compared outcomes for the combination treatment against monotherapies, evaluating whether the combination treatment was associated with changes in pain and joint mobility.

  • Trial Design: The key registrational trials were randomized, double-blind, and placebo-controlled (RCTs). The primary endpoints tracked clinical measures, including the American College of Rheumatology (ACR) response criteria.
  • Observed Response: Analysis of the studies showed a range of observed responses in participants receiving the combination therapy compared to those receiving the placebo or a single active ingredient.

Long-Term Research

Studies explored outcomes related to the drug when used for an extended duration.

  • Study Population: The long-term extension studies focused on participants who had completed the initial 12-month RCT, tracking outcomes over an additional 12–24 months.
  • Symptom Persistence: Clinical trials tracked participant outcomes, observing the range of changes reported within the first 6 weeks and whether the observed effect persisted through the end of the second year.

Subgroup Analysis

Research examined the drug’s association with markers of disease progression.

  • Cardiovascular Events: Clinical studies tracked cardiovascular-related events in participants with pre-existing heart conditions. Further investigation continues regarding outcomes in this patient group.
  • Infections: Studies tracked the rate of infections, including specific opportunistic infections, in participants treated with the drug compared to the placebo group.

Frequently Asked Questions (FAQ)

Common questions about Lindex (FAQ)

Q: What is the main condition Lindex is officially approved to treat?

According to official regulatory documents, Lindex (Memantine Hydrochloride) is indicated for the treatment of moderate-to-severe dementia of the Alzheimer's type. Its general purpose is to support and stabilize cognitive function in adult patients.

Q: What should I know about the different strengths or dosages Lindex comes in?

The active ingredient, Memantine, is manufactured in several forms and strengths. Immediate-release tablets are commonly available in 5 mg and 10 mg strengths. In addition to tablets, the medicine is also available as an oral solution, which may be beneficial for patients who have difficulty swallowing.

Q: What is the general timeline for Lindex to start working?

Official product information notes that the treatment regimen begins with a gradual increase in dosage over the first few weeks. The regulatory label indicates that the benefit of treatment is subject to regular reassessment by a healthcare professional according to current clinical guidelines.

Q: Are there any long-term health concerns associated with using Lindex?

Official information indicates that clinical trials often excluded individuals with certain serious conditions, such as recent heart attacks or uncontrolled high blood pressure. Patients with these health concerns are noted in the label as requiring close supervision by a healthcare professional.

Q: Is Lindex known to cause any skin reactions or rashes?

Regulatory safety information indicates that skin reactions, rashes, itching, blistering, and peeling are documented as rare or uncommon adverse events. Severe skin reactions have also been reported in post-marketing experience.

Q: What common over-the-counter medicines should I be aware of when taking Lindex?

Specific over-the-counter (OTC) products that may interact include NMDA receptor antagonists like dextromethorphan (found in many cough mixtures) and urinary alkalinizing agents like sodium bicarbonate. These are noted in official documents as potentially interacting with Lindex, requiring professional review.

Q: Why do some people need to have blood tests while taking Lindex?

The official label advises that patients taking Lindex alongside certain blood-thinning medicines, such as warfarin, require close monitoring of their International Normalised Ratio (INR). This monitoring helps check for potential effects on blood clotting. Routine monitoring may also be necessary for patients with severe kidney or liver impairment.

Q: What happens if I stop taking Lindex suddenly?

Official administration guidelines state that if treatment is interrupted for several days, it may be necessary to restart the medicine at a lower dose and follow the standard weekly titration schedule. Abrupt cessation has been associated with reports of behavioral disturbance in some patients.

Q: What is the typical monitoring process when a patient is on Lindex?

Tolerance of the medicine and the required dose should be checked regularly, often within the first three months of starting treatment. Official guidance requires that the clinical benefit of Lindex be assessed on an ongoing basis by a healthcare professional.

Q: Is Lindex associated with any mental health side effects like anxiety or depression?

Regulatory documents state that both anxiety and depression are reported as common psychiatric adverse reactions in clinical trials, meaning they affect between 1% and 10% of users. Confusion, agitation, and suicidal ideation have also been documented.

Q: Can Lindex affect my ability to drive or operate machinery?

Official warnings state that Lindex has a minor-to-moderate influence on the ability to drive and use machines, and special care is warranted. Furthermore, the underlying condition being treated may also impair the ability to perform these activities safely.

Q: Does Lindex interact with alcohol?

Official public health information contains advice to avoid or reduce alcohol consumption during treatment. This is because alcohol can worsen existing symptoms associated with the underlying condition, particularly confusion.

Q: Is it normal to feel nauseous when starting Lindex?

Nausea is listed in regulatory documents as a common adverse drug reaction reported in clinical trials, affecting between 1% and 10% of users. Vomiting and other gastrointestinal effects may also occur.

Q: Can Lindex cause weight changes?

Both increased weight and decreased weight are listed in regulatory documents as common metabolic adverse effects reported in clinical trials. A significant change in weight is a reported adverse effect that may warrant professional attention.

Q: Is Lindex known to cause problems with sleep?

Insomnia and general sleep disorder are listed in regulatory safety information as common psychiatric adverse effects. These effects were reported in clinical trials and affect between 1% and 10% of patients.

Q: Can Lindex affect dental health or cause dry mouth?

Official safety documents list dry mouth as a possible adverse effect. While the frequency is not always specified, dry mouth can potentially affect dental health over time. Any persistent side effect is a health concern that may require professional attention.

Q: Is Lindex available in a generic version?

The active ingredient Memantine Hydrochloride is available as a generic medication. The generic version contains the same active drug as the brand name Lindex and is widely available.

How should Lindex be stored and disposed of?

Storage and Disposal Requirements

Requirement Tablets (Film-Coated) Oral Solution
Storage Temperature Store at room temperature (20 C to 25 C), with permitted excursions up to 30 C [FDA]. Some European formulations must not store above 25 C [EMA]. Do not store above 30 C [UK eMC]. Store at room temperature [FDA].
Stability after Opening Not applicable. Must be used within 3 months after the bottle is opened [UK eMC].

Lindex must be stored in a closed container, away from moisture and direct light, and kept from freezing [NIH]. All formulations are required to be kept out of the sight and reach of children [EMA]. For disposal, unused or expired medicine must not be thrown away via wastewater or household waste to help protect the environment [UK eMC]. Patients are directed to ask a pharmacist how to dispose of medicines no longer needed [UK eMC].

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lindex found in:

A-Z Index: